vaccine manufacturing in Africa
-
Africa’s first end-to-end mRNA facility secures SAHPRA approval
Afrigen Biologics has secured SAHPRA GMP certification for its Cape Town mRNA facility—the first end-to-end site in Africa authorised to manufacture investigational biologicals for Phase I/II trials. Discover how this milestone strengthens supply security, pandemic readiness and the WHO-MPP mRNA network.
